Hallek, Michael; Shanafelt, Tait D; Eichhorst, Barbara (abril de 2018). «Chronic lymphocytic leukaemia». The Lancet. 391 (10129): 1524–1537. PMID29477250. doi:10.1016/S0140-6736(18)30422-7
Khan, M; Siddiqi, T (dezembro de 2018). «Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.». Current Hematologic Malignancy Reports. 13 (6): 525–533. PMID30535947. doi:10.1007/s11899-018-0481-7
Hallek, M (setembro de 2017). «Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.». American Journal of Hematology. 92 (9): 946–965. PMID28782884. doi:10.1002/ajh.24826
Ghia P, Guida G, Stella S,; et al. (2003). «The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression». Blood. 101 (4): 1262-9. PMID12406914. doi:10.1182/blood-2002-06-1801 !CS1 manut: Nomes múltiplos: lista de autores (link)
Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R (2006). «Purine antagonists for chronic lymphocytic leukaemia». Cochrane database of systematic reviews (Online). 3: CD004270. PMID16856041. doi:10.1002/14651858.CD004270.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Byrd JC, Peterson BL, Morrison VA,; et al. (2003). «Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)». Blood. 101 (1): 6-14. PMID12393429. doi:10.1182/blood-2002-04-1258 !CS1 manut: Nomes múltiplos: lista de autores (link)
Keating MJ, O'Brien S, Albitar M,; et al. (2005). «Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia». J. Clin. Oncol. 23 (18): 4079-88. PMID15767648. doi:10.1200/JCO.2005.12.051 !CS1 manut: Nomes múltiplos: lista de autores (link)
Boelens, J; Lust, S; Vanhoecke, B; Offner, F (fevereiro de 2009). «Chronic lymphocytic leukaemia.». Anticancer Research. 29 (2): 605–15. PMID19331210
Hallek, Michael; Shanafelt, Tait D; Eichhorst, Barbara (abril de 2018). «Chronic lymphocytic leukaemia». The Lancet. 391 (10129): 1524–1537. PMID29477250. doi:10.1016/S0140-6736(18)30422-7
Khan, M; Siddiqi, T (dezembro de 2018). «Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.». Current Hematologic Malignancy Reports. 13 (6): 525–533. PMID30535947. doi:10.1007/s11899-018-0481-7
Hallek, M (setembro de 2017). «Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.». American Journal of Hematology. 92 (9): 946–965. PMID28782884. doi:10.1002/ajh.24826
Rosenwald A, Alizadeh AA, Widhopf G,; et al. (2001). «Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia». J. Exp. Med. 194 (11): 1639-47. PMID11733578 !CS1 manut: Nomes múltiplos: lista de autores (link)
Ghia P, Guida G, Stella S,; et al. (2003). «The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression». Blood. 101 (4): 1262-9. PMID12406914. doi:10.1182/blood-2002-06-1801 !CS1 manut: Nomes múltiplos: lista de autores (link)
Tsimberidou AM, Keating MJ. Cancer. 2005 Jan 15;103(2):216-28. "Richter syndrome: biology, incidence, and therapeutic strategies. PMID 15578683 "
Cheson BD, Bennett JM, Grever M,; et al. (1996). «National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment». Blood. 87 (12): 4990-7. PMID8652811 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rai KR, Peterson BL, Appelbaum FR,; et al. (2000). «Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia». N. Engl. J. Med. 343 (24): 1750-7. PMID11114313 !CS1 manut: Nomes múltiplos: lista de autores (link)
Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R (2006). «Purine antagonists for chronic lymphocytic leukaemia». Cochrane database of systematic reviews (Online). 3: CD004270. PMID16856041. doi:10.1002/14651858.CD004270.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Byrd JC, Peterson BL, Morrison VA,; et al. (2003). «Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)». Blood. 101 (1): 6-14. PMID12393429. doi:10.1182/blood-2002-04-1258 !CS1 manut: Nomes múltiplos: lista de autores (link)
Keating MJ, O'Brien S, Albitar M,; et al. (2005). «Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia». J. Clin. Oncol. 23 (18): 4079-88. PMID15767648. doi:10.1200/JCO.2005.12.051 !CS1 manut: Nomes múltiplos: lista de autores (link)
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT (2003). «Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning». Leukemia. 17 (5): 841-8. PMID 12750695 !CS1 manut: Nomes múltiplos: lista de autores (link)
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002). «Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study». Blood. 99 (10): 3554-61. PMID 11986207 !CS1 manut: Nomes múltiplos: lista de autores (link)